| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20710 | AZ0108 | AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively. |
|
| DC11147 | AZ084 | AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM. |
|
| DC20314 | AZ-1 | AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity. |
|
| DC11975 | AZ 10397767 | AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0. |
|
| DC20711 | AZ10606120 dihydrochloride Featured | AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively. |
|
| DC12613 | AZ12204657 | AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM. |
|
| DC22724 | AZ12441970 | AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8. |
|
| DC12530 | AZ12601011 | AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM. |
|
| DC12531 | AZ12799734 | AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF |
|
| DC21406 | AZ-1355 | AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.. |
|
| DC20712 | AZ13705339 Featured | AZ13705339 is a potent, selective PAK1 inhibitor with IC50 of 0.33 nM, displays 14-, 470-, 4100- and 2600-fold selectivity over Src, FGFR1, KDR and PAK4. |
|
| DC20713 | AZ13711265 | AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4. |
|
| DC23484 | AZ1729 | AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways. |
|
| DC20315 | AZ-2 | AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity. |
|
| DC23855 | AZ-23 | AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively. |
|
| DC20715 | AZ-4217 | AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells. |
|
| DC10985 | AZ6197 | AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively. |
|
| DC12274 | AZ82 | AZ82 is a selective HSET/KIFC1 inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1. |
|
| DC11742 | AZ-8838 | AZ-8838 (AZ8838) is a potent, and selective PAR2 antagonist with Kd of 125 nM. |
|
| DC23407 | AZ8838 racemate | AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM.. |
|
| DC10056 | AZ9482 Featured | AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine. |
|
| DC8713 | Azaperone | Azaperone acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in |
|
| DC9469 | Azatadine (dimaleate) | Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. |
|
| DC23851 | AZD 0424 | AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity.. |
|
| DC20720 | AZD 1678 | AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4. |
|
| DC23588 | AZD 3043 | AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM. |
|
| DC8658 | AZD3264 | AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. |
|
| DC20726 | AZD 4205 Featured | AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo. |
|
| DC23722 | AZD 6610 | AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.. |
|
| DC20730 | AZD 7009 | AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM. |
|
